Exozymes (EXOZ) CSO logs small April open-market stock sales

Rhea-AI Filing Summary

EXOZYMES INC. Chief Scientific Officer Korman Tyler Paz reported small open-market sales of company common stock. On April 8, Paz sold 750 shares at an average price of $10.0406 per share, followed by another 750 shares on April 9 at $10.525 per share.

Across the two days Paz sold a total of 1,500 shares and now directly holds 729,123 shares of EXOZYMES INC. common stock. The transactions are classified as open-market sales of non-derivative common stock.

Insider Trade Summary

Net Seller: 1,500 shares ($15,424)

Net Sell 2 txns

Insider Korman Tyler Paz

Role Chief Scientific Officer

Sold 1,500 shs ($15K)

Type	Security	Shares	Price	Value
Sale	COMMON STOCK	750	$10.525	$8K
Sale	COMMON STOCK	750	$10.0406	$8K

Holdings After Transaction: COMMON STOCK — 729,123 shares (Direct)

Footnotes (1)

Key Figures

Shares sold April 8: 750 shares at $10.0406 Shares sold April 9: 750 shares at $10.525 Total shares sold: 1,500 shares +2 more

5 metrics

Shares sold April 8 750 shares at $10.0406 Open-market sale of common stock on April 8, 2026

Shares sold April 9 750 shares at $10.525 Open-market sale of common stock on April 9, 2026

Total shares sold 1,500 shares Net shares sold across two open-market transactions

Shares held after transactions 729,123 shares Direct common stock ownership after April 2026 sales

Number of sell transactions 2 sales Two separate open-market sales reported in Form 4

Key Terms

open-market sale, non-derivative, COMMON STOCK, direct ownership

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type": "non-derivative""

COMMON STOCK financial

"security_title": "COMMON STOCK""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

direct ownership financial

"ownership_type": "direct""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Korman Tyler Paz

(Last) (First) (Middle)

C/O 750 ROYAL OAKS DRIVE,

SUITE 106

(Street)

MONROVIA CALIFORNIA 91016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	04/08/2026	04/08/2026	S		750	D	$10.0406	729,873	D
COMMON STOCK	04/09/2026	04/09/2026	S		750	D	$10.525	729,123	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Tyler Korman	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did EXOZ (Exozymes Inc.) disclose in this Form 4?

Exozymes Inc. disclosed that Chief Scientific Officer Korman Tyler Paz sold 1,500 shares of common stock in two open-market transactions, while retaining 729,123 shares directly. These sales involved non-derivative common stock and were reported as routine insider activity.

How many EXOZ shares did the Chief Scientific Officer sell and at what prices?

Korman Tyler Paz sold a total of 1,500 EXOZ shares. He sold 750 shares at an average price of $10.0406 on April 8 and another 750 shares at $10.525 on April 9, according to the reported Form 4 transactions.

How many EXOZ shares does Korman Tyler Paz hold after these transactions?

After the reported sales, Korman Tyler Paz holds 729,123 shares of Exozymes Inc. common stock directly. This post-transaction balance reflects his remaining ownership following the two small open-market sales disclosed in the Form 4 filing.

Were the EXOZ insider transactions derivative or non-derivative securities?

The reported EXOZ insider transactions involved non-derivative common stock. Both sales were categorized as open-market sales of common stock, with no options, warrants, or other derivative securities listed in the transaction details or derivative holdings summary.

What is the net effect of the reported EXOZ insider transactions on share ownership?

The net effect is a reduction of 1,500 EXOZ shares in Korman Tyler Paz’s direct holdings. He sold 1,500 shares across two days, resulting in a post-transaction direct ownership position of 729,123 common shares, as reflected in the Form 4 data.